-
Document de presse | 2023.11.14
Significant "post-COVID" resurgence in invasive meningococcal disease
A team of scientists from the Institut Pasteur has used the database of the National Reference Center for Meningococci to trace the evolution of invasive meningococcal disease cases in France between 2015 and 2022, revealing an unprecedented resurgence in the disease after the easing of control measures imposed during the COVID-19 epidemic. Recently reported cases have mainly been caused by...
-
News | 2020.04.28
International Network of Pasteur Institutes: deepening the scientific collective strategy
Three years ago, the scientific community of the Institut Pasteur International Network (IPIN) expressed its desire to build a comprehensive strategy in order to strengthen its positioning and establish itself as a global public health authority. The Scientific Steering Committee of the Institut Pasteur International Network(COS-RIIP) was created in August 2019 to help achieve this goal....
-
News | 2020.12.01
Use of the maladiecoronavirus.fr web application during the first wave helped reduce call volumes to the French medical emergency number
The maladiecoronavirus.fr web application is a self-triage tool for suspected COVID-19 cases. It was the first application to be approved by the French Ministry of Health in March 2020, and has since been used by almost 13 million people. A study has demonstrated that use of maladiecoronavirus.fr led to an eightfold reduction in the number of unnecessary calls to the French medical emergency...
-
Document de presse | 2024.02.22
New epidemiological surveillance indicators for more effective monitoring of suicide attempts
Teams from the Child and Adolescent Psychiatry Department at Robert Debré Hospital (AP-HP), the AP-HP Digital Services Department and the Institut Pasteur, coordinated by Romain Bey and Prof. Richard Delorme, have developed novel digital tools to improve mental health monitoring for people living in the Greater Paris region. The data in this retrospective study were generated by analyzing several...
-
Document de presse | 2024.05.28
AFROSCREEN: a key network for genomic surveillance in Sub-Saharan Africa
Three years after its launch, AFROSCREEN meets all its objectives, developing effective genomic surveillance to tackle epidemics in sub-Saharan Africa The AFROSCREEN project, financed to the tune of €10 million by Agence Française de Développement (AFD), has been working since 2021 to set up or strengthen sequencing platforms and build an operational network for monitoring emerging...
-
Article | 2020.06.16
Evolution of SARS-CoV-2 and the antibody immune response in humans during infection
Aim: to understand the evolution of the SARS-CoV-2 viral population in hosts during illness, in relation with the infectivity of the virus and the establishment of the humoral (antibody-based) immune response. This knowledge is important to identify trends in disease progression and help improve the treatment and post-treatment follow-up given to patients. Detailed data on the evolution of...
-
Document de presse | 2020.10.15
Innate immunity and fusion of cells infected with SARS-CoV-2
Innate immunity is the fastest-acting component of the immune system, but so far little is known about its role during infection with SARS-CoV-2. A few hours after an infection, the body emits an alarm signal, interferon, enabling cells that have not yet been infected to produce antiviral proteins. This phenomenon occurs well before the production of neutralizing antibodies. Scientists from the...
-
Document de presse | 2021.07.21
SARS-CoV-2 damages ciliated cells and inhibits mucociliary clearance in the airways
COVID-19 is a viral disease with respiratory symptoms that can induce fatal pneumonia. Understanding how SARS-CoV-2 spreads in the respiratory tract can help scientists identify the parameters controlling the severity of infection. Scientists from the Institut Pasteur, the CNRS and Inserm found that SARS-CoV-2 multiplies efficiently in the respiratory tract, and that it primarily targets ciliated...
-
News | 2021.09.09
SPKM001, a promising anti-SARS-CoV-2 monoclonal antibody, is being developed by the Institut Pasteur and SpikImm
Following encouraging initial results, which will be published shortly, the Institut Pasteur and SpikImm announce the development of the antibody SPKM001.Paris, September 9, 2021SPKM001 is a high affinity human monoclonal antibody which targets the receptor-binding site (RBD) on the Spike protein of the original SARS-CoV-2 strain and its variants.Initial preclinical results tend to show that this...
-
Document de presse | 2021.09.27
SARS-CoV-2: different immune responses observed in nasal mucosa and blood
The clinical manifestations of SARS-CoV-2 infection vary from one individual to the next, and much remains unknown about the mechanisms underpinning this variability. Since the nasal mucosa is one of the first entry points of the virus, scientists from the Institut Pasteur and Inserm, in collaboration with Cochin AP-HP Hospital, analyzed in parallel the immune responses in the nasal mucosa and in...
